Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Döhner

Showing results (21-30 of 490) with videos related to

Pageof 49
Sort By:
The New England Journal of Medicine|June 29, 2022
Ivosidenib and Azacitidine in IDH1-Mutated AML. ReplyPau Montesinos, Stephane de Botton, Hartmut Döhner
Blood|June 10, 2021
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimalElihu Estey, Robert P Hasserjian, Hartmut Döhner
Nature Reviews. Clinical Oncology|May 19, 2021
Towards precision medicine for AMLHartmut Döhner, Andrew H Wei, Bob Löwenberg
The New England Journal of Medicine|September 1, 2016
Genomic Classification in Acute Myeloid LeukemiaElli Papaemmanuil, Hartmut Döhner, Peter J Campbell
Blood Reviews|March 26, 2011
Importance of genetics in chronic lymphocytic leukemiaThorsten Zenz, Daniel Mertens, Hartmut Döhner, et al.
The New England Journal of Medicine|September 17, 2015
Acute Myeloid LeukemiaHartmut Döhner, Daniel J Weisdorf, Clara D Bloomfield
The New England Journal of Medicine|March 31, 2021
Oral Azacitidine Maintenance for Acute Myeloid Leukemia. ReplyAndrew H Wei, Hartmut Döhner, Gail J Roboz
Leukemia & Lymphoma|May 3, 2008
Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implicationsThorsten Zenz, Daniel Mertens, Hartmut Döhner, et al.
Cell Cycle (Georgetown, Tex.)|December 23, 2008
Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathwayThorsten Zenz, Axel Benner, Hartmut Döhner, et al.
The New England Journal of Medicine|November 9, 2017
Midostaurin in FLT3-Mutated Acute Myeloid LeukemiaRichard M Stone, Richard A Larson, Hartmut Döhner
Pageof 49

Showing results (21-30 of 490) with videos related to

Sort By:
Pageof 49
The New England Journal of Medicine|June 29, 2022
Ivosidenib and Azacitidine in IDH1-Mutated AML. ReplyPau Montesinos, Stephane de Botton, Hartmut Döhner
Blood|June 10, 2021
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimalElihu Estey, Robert P Hasserjian, Hartmut Döhner
Nature Reviews. Clinical Oncology|May 19, 2021
Towards precision medicine for AMLHartmut Döhner, Andrew H Wei, Bob Löwenberg
The New England Journal of Medicine|September 1, 2016
Genomic Classification in Acute Myeloid LeukemiaElli Papaemmanuil, Hartmut Döhner, Peter J Campbell
Blood Reviews|March 26, 2011
Importance of genetics in chronic lymphocytic leukemiaThorsten Zenz, Daniel Mertens, Hartmut Döhner, et al.
The New England Journal of Medicine|September 17, 2015
Acute Myeloid LeukemiaHartmut Döhner, Daniel J Weisdorf, Clara D Bloomfield
The New England Journal of Medicine|March 31, 2021
Oral Azacitidine Maintenance for Acute Myeloid Leukemia. ReplyAndrew H Wei, Hartmut Döhner, Gail J Roboz
Leukemia & Lymphoma|May 3, 2008
Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implicationsThorsten Zenz, Daniel Mertens, Hartmut Döhner, et al.
Cell Cycle (Georgetown, Tex.)|December 23, 2008
Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathwayThorsten Zenz, Axel Benner, Hartmut Döhner, et al.
The New England Journal of Medicine|November 9, 2017
Midostaurin in FLT3-Mutated Acute Myeloid LeukemiaRichard M Stone, Richard A Larson, Hartmut Döhner
Pageof 49